Company News Ractigen Therapeutics Announces the Appointment of Harri Järveläinen as Chief Operating Officer SUZHOU, Jiangsu, China -- Ractigen Therapeutics, Inc. announced today that Dr. Harri Järveläinen has been…ractigenJanuary 9, 2023
Company News Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform Ractigen Therapeutics today announced the closing of a Series A+ financing round totaling $30 million…EnvisionJanuary 27, 2022
Company News Ractigen Therapeutics closes on $17 Million Series A to advance lead program into clinical phase, led by Hillhouse Venture Capital Ractigen Therapeutics, a leading company in the saRNA drug space, announced that it has closed…EnvisionFebruary 10, 2021
Company News CB Insights lists Ractigen as one of the Top RNA biotech companies in China Today, CB Insights China published, for the first time, a top list of RNA biotech…EnvisionMay 19, 2020
Company News Delegation from Nantong University Medical School visits Ractigen Today, a 5-member delegation, led by the dean Professor Fei Sun, from Nantong University Medical…EnvisionJuly 11, 2018
Company News Scientists from Ractigen and KRIBB publish new study on saRNA-guided activation of VHL gene in renal cell carcinoma Today, an article entitled "Small activating RNA induced expression of VHL gene in renal cell…EnvisionFebruary 7, 2018
Company News The first book on RNAa published Springer•Nature published a book edited by Ractigen’s founder, Dr. Long-Cheng LI and entitled “RNA Activation”.…EnvisionJuly 12, 2017
Company News HS Talk published a lecture presented by Ractigen’s co-founder and CEO, Dr. Long-Cheng Li Henry Stewart Talks which publishes animated audio visual presentations by world leading experts published a…EnvisionApril 30, 2017